$207B Market Shift: The Race for Fast Track Approval in Oncology $207B Market Shift: The Race for Fast Track Approval in Oncology PR Newswire VANCOUVER, BC, Feb. 5, 2026 Issued on behalf of...
The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.